440 related articles for article (PubMed ID: 26318099)
21. NBOMes-Highly Potent and Toxic Alternatives of LSD.
Zawilska JB; Kacela M; Adamowicz P
Front Neurosci; 2020; 14():78. PubMed ID: 32174803
[TBL] [Abstract][Full Text] [Related]
22. 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists.
McLean TH; Parrish JC; Braden MR; Marona-Lewicka D; Gallardo-Godoy A; Nichols DE
J Med Chem; 2006 Sep; 49(19):5794-803. PubMed ID: 16970404
[TBL] [Abstract][Full Text] [Related]
23. Unraveling the In Vitro Toxicity Profile of Psychedelic 2C Phenethylamines and Their
Martins D; Gil-Martins E; Cagide F; da Fonseca C; Benfeito S; Fernandes C; Chavarria D; Remião F; Silva R; Borges F
Pharmaceuticals (Basel); 2023 Aug; 16(8):. PubMed ID: 37631071
[TBL] [Abstract][Full Text] [Related]
24. Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe.
Tang MH; Ching CK; Tsui MS; Chu FK; Mak TW
Clin Toxicol (Phila); 2014 Jun; 52(5):561-5. PubMed ID: 24779864
[TBL] [Abstract][Full Text] [Related]
25. Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response.
Halberstadt AL; Geyer MA
Neuropharmacology; 2014 Feb; 77():200-7. PubMed ID: 24012658
[TBL] [Abstract][Full Text] [Related]
26. Detailed Characterization of the In Vitro Pharmacological and Pharmacokinetic Properties of
Jensen AA; McCorvy JD; Leth-Petersen S; Bundgaard C; Liebscher G; Kenakin TP; Bräuner-Osborne H; Kehler J; Kristensen JL
J Pharmacol Exp Ther; 2017 Jun; 361(3):441-453. PubMed ID: 28360333
[TBL] [Abstract][Full Text] [Related]
27. 1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist.
Nichols DE; Frescas S; Marona-Lewicka D; Huang X; Roth BL; Gudelsky GA; Nash JF
J Med Chem; 1994 Dec; 37(25):4346-51. PubMed ID: 7996545
[TBL] [Abstract][Full Text] [Related]
28. Argyreia nervosa (Burm. f.): receptor profiling of lysergic acid amide and other potential psychedelic LSD-like compounds by computational and binding assay approaches.
Paulke A; Kremer C; Wunder C; Achenbach J; Djahanschiri B; Elias A; Schwed JS; Hübner H; Gmeiner P; Proschak E; Toennes SW; Stark H
J Ethnopharmacol; 2013 Jul; 148(2):492-7. PubMed ID: 23665164
[TBL] [Abstract][Full Text] [Related]
29. New 5-HT
Fiorino F; Magli E; Kędzierska E; Ciano A; Corvino A; Severino B; Perissutti E; Frecentese F; Di Vaio P; Saccone I; Izzo AA; Capasso R; Massarelli P; Rossi I; Orzelska-Gòrka J; Kotlińska JH; Santagada V; Caliendo G
Bioorg Med Chem; 2017 Oct; 25(20):5820-5837. PubMed ID: 28943244
[TBL] [Abstract][Full Text] [Related]
30. Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs.
Zuba D; Sekuła K
Drug Test Anal; 2013 Aug; 5(8):634-45. PubMed ID: 22936468
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists.
Hansen M; Jacobsen SE; Plunkett S; Liebscher GE; McCorvy JD; Bräuner-Osborne H; Kristensen JL
Bioorg Med Chem; 2015 Jul; 23(14):3933-7. PubMed ID: 25583099
[TBL] [Abstract][Full Text] [Related]
32. 25B-NBOMe, a novel N-2-methoxybenzyl-phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: Evidence of abuse potential.
Custodio RJP; Sayson LV; Botanas CJ; Abiero A; You KY; Kim M; Lee HJ; Yoo SY; Lee KW; Lee YS; Seo JW; Ryu IS; Kim HJ; Cheong JH
Addict Biol; 2020 Nov; 25(6):e12850. PubMed ID: 31749223
[TBL] [Abstract][Full Text] [Related]
33. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes.
Villalobos CA; Bull P; Sáez P; Cassels BK; Huidobro-Toro JP
Br J Pharmacol; 2004 Apr; 141(7):1167-74. PubMed ID: 15006903
[TBL] [Abstract][Full Text] [Related]
34. 5-HT2 receptor binding, functional activity and selectivity in N-benzyltryptamines.
Toro-Sazo M; Brea J; Loza MI; Cimadevila M; Cassels BK
PLoS One; 2019; 14(1):e0209804. PubMed ID: 30629611
[TBL] [Abstract][Full Text] [Related]
35. Neurochemical binding profiles of novel indole and benzofuran MDMA analogues.
Shimshoni JA; Winkler I; Golan E; Nutt D
Naunyn Schmiedebergs Arch Pharmacol; 2017 Jan; 390(1):15-24. PubMed ID: 27650729
[TBL] [Abstract][Full Text] [Related]
36. Effect of Bulky
Soares BA; Yempala T; Martínez-Afani D; Acevedo-Fuentes W; Brea J; Loza MI; Cimadevila M; Cassels BK
ACS Chem Neurosci; 2024 Feb; 15(3):608-616. PubMed ID: 38241462
[TBL] [Abstract][Full Text] [Related]
37. N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues.
Nichols DE; Sassano MF; Halberstadt AL; Klein LM; Brandt SD; Elliott SP; Fiedler WJ
ACS Chem Neurosci; 2015 Jul; 6(7):1165-75. PubMed ID: 25547199
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists.
Hansen M; Phonekeo K; Paine JS; Leth-Petersen S; Begtrup M; Bräuner-Osborne H; Kristensen JL
ACS Chem Neurosci; 2014 Mar; 5(3):243-9. PubMed ID: 24397362
[TBL] [Abstract][Full Text] [Related]
39. 2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine (25D-NBOMe) and N-(2-methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe) induce adverse cardiac effects in vitro and in vivo.
Yoon KS; Yun J; Kim YH; Shin J; Kim SJ; Seo JW; Hyun SA; Suh SK; Cha HJ
Toxicol Lett; 2019 Apr; 304():50-57. PubMed ID: 30658151
[TBL] [Abstract][Full Text] [Related]
40. Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases.
Wagmann L; Brandt SD; Stratford A; Maurer HH; Meyer MR
Drug Test Anal; 2019 Feb; 11(2):318-324. PubMed ID: 30188017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
